Drug & Alcohol Screening Market - Forecast(2024 - 2030)
Drug & Alcohol Screening Market Overview
The Drug & Alcohol Screening Market size is estimated to reach $14.7 billion by 2028, growing at a CAGR of 14.5% during the forecast period 2023-2028. The increasing application of prohibited drugs and alcohol that requires breath alcohol testing is set to drive the Drug & Alcohol Screening Market. The great technological progress is also set to propel the growth of the Drug & Alcohol Screening Industry during the forecast period 2023-2028. A urine drug test is the most typically utilized test when job applicants or employees are screened for prohibited drugs or alcohol consumption. Breath alcohol testing is normally carried out as a portion of workplace drug tests. The permissible limit is 35 micrograms of alcohol in 100 milliliters of breath in an alcohol breath test. Suspicious people with breath test readings between 36 and below 40 need to be discharged with caution or without charge. Drug testing laboratories need to be certified by the Department of Health and Human Services. Hair strand drug tests can be utilized to detect virtually all drug and alcohol substances between seven days and six months following their utilization. LC-MS (liquid chromatography-mass spectrometry) provides the “gold standard” confirmation of drug utilization. This represents the Drug & Alcohol Screening Industry Outlook.
Drug & Alcohol Screening Market Report Coverage
The “Drug & Alcohol Screening
Market Report - Forecast (2023-2028)” by IndustryARC, covers an
in-depth analysis of the following segments in the Drug & Alcohol Screening Market.
Key Takeaways
- Geographically, North America (Drug & Alcohol Screening Market share) accounted for the highest revenue share in 2022. It is also poised to dominate the market over the period 2023-2028 owing to increasing consumption of illegal drugs and alcohol, requiring workplace drug tests in the North American region.
- Drug & Alcohol Screening Market growth is being driven by the increasing consumption of illegal drugs and alcohol among youth, requiring breath alcohol testing. However, constraints forbidding drug testing at work, specifically in developed economies are some of the major factors hampering the growth of the Drug & Alcohol Screening Market.
- Drug & Alcohol Screening Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Drug & Alcohol Screening Market report.
Drug & Alcohol Screening Market Segment Analysis - by Sample Type
The Drug & Alcohol Screening Market based on sample type can be further segmented into Urine Samples, Oral Fluid Samples, Hair Samples and Others. The Urine Samples Segment held the largest share of the Drug & Alcohol Screening Market in 2022. This growth is driven by the increasing application of urine testing for drugs. The advantages of urine testing include non-invasiveness and the capability to detect a huge number of drugs in the sample. The rising application of urine drug testing for monitoring patients with long-term opioid therapy is further propelling the growth of the Urine Samples segment. Furthermore, the Urine Samples segment is estimated to grow at the fastest CAGR of 15.3% during the forecast period 2023-2028. This is due to the growing application of urine drug testing as one of the critical tests to inspect opioid dependency.
Drug
& Alcohol Screening Market Segment Analysis - by Application
The Drug & Alcohol Screening Market based on the application can be further segmented into Workplace, Criminal Justice Systems And Law Enforcement Agencies, Drug Treatment Centers, Pain Management Centers, Drug Testing Laboratories and Others. The Workplace Segment held the largest share of the Drug & Alcohol Screening Market in 2022. This growth is fueled by the extensive application of drug & alcohol screening in the workplace to examine workers. Jobfit Health Group offers an extensive spectrum of workplace healthy services in Australia. The increasing application of urine or saliva tests is further propelling the growth of this segment. Furthermore, the Criminal Justice Systems And Law Enforcement Agencies segment is estimated to grow with the fastest CAGR of 16.5% during the forecast period 2023-2028 due to the increasing predominance of the opioid outbreak, resulting in drug-associated imprisonments.
Drug & Alcohol Screening Market Segment Analysis - by Geography
North America (Drug & Alcohol Screening Market) dominated the Drug & Alcohol Screening Market with a 41% share of the overall market in 2022. The growth of this region is driven by the extensive alcohol misapplication in the North American region. The strict regulations are further propelling the growth of the Drug & Alcohol Screening Industry, thereby contributing to the Drug & Alcohol Screening Industry Outlook, in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. This growth is fueled by the factors like increasing drug & alcohol screening in hospitals in the Asia-Pacific region. The rising awareness of drug screening policy is further fueling the progress of the Drug & Alcohol Screening Market in the Asia-Pacific region.
Drug & Alcohol Screening Market Drivers
Vital Significance of Breath Alcohol Test:
A breath alcohol test decides how much alcohol is in the blood. The test assesses the quantity of alcohol in the air one exhales. One needs to wait 15 minutes after consuming an alcoholic beverage and 1 minute after smoking before beginning the test. When the percentage reaches 0.05% to 0.10%, one may endure decreased muscle coordination, a lengthier reaction time and faulty judgment and responses. The vital significance of the Breath Alcohol Test is therefore fueling the growth of the Drug & Alcohol Screening Market during the forecast period 2023-2028.
Increasing Count of Laboratories for Drug & Alcohol Screening:
The Federal Motor Carrier Safety Administration (FMCSA) declared that for 2022, alcohol testing would stay at 10%. Soteria Screening Laboratories is an online Third Party Administration (TPA) that offers the application and handling of DOT and non-DOT Drug and Alcohol Testing Programs. Western Diagnostic Pathology is the chief provider of drug and alcohol testing services in Western Australia. The laboratories follow strict quality standards. The increasing count of laboratories for drug and alcohol screening is therefore driving the growth of the Drug & Alcohol Screening Industry, thereby contributing to the Drug & Alcohol Screening Industry Outlook during the forecast period 2023-2028.
Drug & Alcohol Screening Market Challenges
Disadvantages of Workplace Drug Testing Like Random Drug Testing that's Not Performed in Real Time:
Random drug testing is not performed in real time. It just brings to the knowledge of the employer that the employee utilized a particular drug, sometime in the past. This is not always beneficial since the principal priority is to discourage intoxication while employees are at work. Drug testing is not considered a safety measure. Numerous job candidates take a break from utilizing drugs when they know that they have a drug screen. As per novel research, drug tests typically generate false positive results in 5% to 10% of cases. These issues are thus hampering the growth of the Drug & Alcohol Screening Market.
Drug & Alcohol Screening Industry Outlook
Novel product development, mergers and acquisitions and geographical expansions are key strategies adopted by players in the Drug & Alcohol Screening Market. The top 10 companies in the Drug & Alcohol Screening Market are:
- Quest Diagnostics
- Labcorp (Laboratory Corporation of America Holdings)
- Drägerwerk AG & Co. KGaA
- Thermo Fisher Scientific Inc.
- Alfa Scientific Designs, Inc.
- Omega Laboratories, Inc.
- Roche Diagnostics Corporation (a diagnostic division of F. Hoffmann-La Roche AG)
- Siemens Healthineers AG
- Premier Biotech, Inc.
- Psychemedics Corporation
Recent Developments
- In August 2022, Quest Diagnostics declared the introduction of a novel obstetrics laboratory test panel. It would permit physicians to screen all eligible pregnant people effortlessly. This is targeted toward hepatitis C (HCV).
- In December 2021, Labcorp declared that it had closed its acquisition of Toxikon Corporation. Toxikon Corporation is a contract research organization. This gain helps Labcorp’s powerful nonclinical development portfolio.
- In July 2021, Labcorp declared that it is extending its oncology portfolio by gaining OmniSeq. The transaction helps Labcorp’s growing portfolio of diagnostic tests and clinical trial opportunities. It is targeted toward people with cancer and the oncologists who treat them.
Relevant Reports:
Report
Code: HCR 0386
Report Code: CMR 0993
Report Code: HCR 0447
For more Lifesciences and Healthcare Market reports, please click here